An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer

BACKGROUND. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) are believed to mediate angiogenesis in colorectal cancer (CRC). Ramucirumab (RAM; IMC-1121B) is a human IgG1 monoclonal antibody that inhibits VEGF ligand binding to VEGFR-2, inhibiting VEGFR-2 activation and signal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Garcia-Carbonero, Rocio, Rivera, Fernando, Maurel, Joan, Ayoub, Jean-Pierre M., Moore, Malcolm J., Cervantes, Andres, Asmis, Timothy R., Schwartz, Jonathan D., Nasroulah, Federico, Ballal, Shaila, Tabernero, Josep
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983832/
https://ncbi.nlm.nih.gov/pubmed/24674871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados